Company Interview / Digital health on a world stage: Alcidion’s big play

Key points:

Alcidion (ASX:ALC) named preferred provider for Sussex hospital trust contract in the UKSignificant expansion of Defence Force contract with Leidos AustraliaStrong cash flow, no debt, focus on further international marketsGrowing credibility through successful platform delivery in multiple regions

Kate Quirke of Alcidion points to strong momentum for the company, highlighted by major contract wins and global expansion. Quirke notes Alcidion has been named preferred provider for a significant electronic patient record platform at University Hospitals Foundation Trust in Sussex, one of the largest trusts in England. She expects this contract, still under negotiation, to be worth at least $35 million over a minimum of seven years, reinforcing ongoing growth through FY25 and FY26. This would mark Alcidion’s (ASX:ALC) third contract of this type and underlines its increasing presence in the UK.

Alcidion's relationship with Leidos Australia also receives mention, as Quirke outlines a $15.4 million uplift in quarterly sales following a substantial expansion of their Australian Defence Force digital health platform contract. The original deal, structured as a potential 15-year agreement, is now valued at over $5.5 million in recurring annual revenue. Quirke states the business maintains strong cash flow and balance sheet, has no debt, and is focused on strategic international growth, with attention to new markets in Canada and the Middle East.

Quirke highlights a growing evidence base and references from established sites across Australia, New Zealand, and the UK as crucial for healthcare sector credibility, positioning Alcidion to further capture market share and deliver shareholder returns as profitability and customer momentum continue.